Form 4: AEON Biopharma CEO Marc Forth Awarded Stock Options

AEON Biopharma's CEO, Marc Forth, received a grant of 212,466 stock options on March 19, 2024, vesting over four years.

Summary

• Marc Forth, the CEO of AEON Biopharma, was granted 212,466 stock options on March 19, 2024.
• The options have an exercise price of $14.40.
• The options vest in equal installments annually over four years, starting on the first anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicit negative indicators.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Risks

• The value of the stock options is dependent on the future performance of AEON Biopharma's stock price, which is subject to market risks and company-specific factors.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biopharmaceutical industry to incentivize executives and align their interests with shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.

Key Dates

Keywords

stock options, AEON Biopharma, Marc Forth, CEO, equity, incentive, vesting